Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study

IF 4 3区医学 Q2 VIROLOGY

Journal of Clinical Virology Pub Date : 2023-12-31 DOI:10.1016/j.jcv.2023.105635

Paul Loubet , Jérôme Fernandes , Gérard de Pouvourville , Katia Sosnowiez , Anne Elong , Caroline Guilmet , Hanane Omichessan , Isabelle Bureau , Francis Fagnani , Corinne Emery , Claire Nour Abou Chakra

{"title":"Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study","authors":"Paul Loubet , Jérôme Fernandes , Gérard de Pouvourville , Katia Sosnowiez , Anne Elong , Caroline Guilmet , Hanane Omichessan , Isabelle Bureau , Francis Fagnani , Corinne Emery , Claire Nour Abou Chakra","doi":"10.1016/j.jcv.2023.105635","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Respiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTI) that may lead to hospitalization or death. The present study aimed to assess the burden of RSV infections in hospitalized adults.</p></div><div><h3>Methods</h3><p>RSV-related hospitalizations were identified from the nationwide hospital claims database in France (PMSI) from 2012 to 2021 using ICD-10 codes J12.1, J20.5, J21.0 or B97.4, and outcomes assessment focused on 2016–2020. In-hospital outcomes included length of stay, need for intensive care (ICU) and in-hospital all-cause mortality. Post-discharge outcomes included 30-day readmission for decompensation, 90-day RSV-related readmission, and 30 and 60-day in-hospital mortality.</p></div><div><h3>Results</h3><p>A cumulated number of 17 483 RSV-related stays were identified representing a rate of 72.0 cases per million stays. The outcomes assessment included 12,987 patients: 55.8 % were females and the mean age was 74.1 ± 16.4 years, with 57 % ≥ 75 years. Most of patients (78.6 %) had at least one comorbidity, mainly chronic respiratory (56.3 %) and cardiovascular diseases (41.3 %), or diabetes (23.5 %). A co-infection was found in 22.4 %, primarily bacterial (12 %). The mean length of stay was 12.3 ± 13.1 days. Overall, 10.9 % were admitted to an ICU and in-hospital mortality was 7.3 %. In-hospital outcomes were higher in cases of co-infection. Among 12 033 patients alive at discharge from the index stay, 6.5 % were readmitted with RSV within 90 days, 8.1 % for decompensation within 30 days, and 5.6 % died within 60-day.</p></div><div><h3>Conclusion</h3><p>This study demonstrated the high burden of RSV infections in older adults and those with chronic conditions, and the need for preventive strategies.</p></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"171 ","pages":"Article 105635"},"PeriodicalIF":4.0000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1386653223002585","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Respiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTI) that may lead to hospitalization or death. The present study aimed to assess the burden of RSV infections in hospitalized adults.

Methods

RSV-related hospitalizations were identified from the nationwide hospital claims database in France (PMSI) from 2012 to 2021 using ICD-10 codes J12.1, J20.5, J21.0 or B97.4, and outcomes assessment focused on 2016–2020. In-hospital outcomes included length of stay, need for intensive care (ICU) and in-hospital all-cause mortality. Post-discharge outcomes included 30-day readmission for decompensation, 90-day RSV-related readmission, and 30 and 60-day in-hospital mortality.

Results

A cumulated number of 17 483 RSV-related stays were identified representing a rate of 72.0 cases per million stays. The outcomes assessment included 12,987 patients: 55.8 % were females and the mean age was 74.1 ± 16.4 years, with 57 % ≥ 75 years. Most of patients (78.6 %) had at least one comorbidity, mainly chronic respiratory (56.3 %) and cardiovascular diseases (41.3 %), or diabetes (23.5 %). A co-infection was found in 22.4 %, primarily bacterial (12 %). The mean length of stay was 12.3 ± 13.1 days. Overall, 10.9 % were admitted to an ICU and in-hospital mortality was 7.3 %. In-hospital outcomes were higher in cases of co-infection. Among 12 033 patients alive at discharge from the index stay, 6.5 % were readmitted with RSV within 90 days, 8.1 % for decompensation within 30 days, and 5.6 % died within 60-day.

Conclusion

This study demonstrated the high burden of RSV infections in older adults and those with chronic conditions, and the need for preventive strategies.

查看原文本刊更多论文

2012 至 2021 年法国成人呼吸道合胞病毒相关住院情况：全国医院数据库研究

背景呼吸道合胞病毒（RSV）可引起下呼吸道感染（LRTI），导致住院或死亡。本研究旨在评估RSV感染给住院成人带来的负担。方法从法国全国医院索赔数据库（PMSI）中确定2012年至2021年与RSV相关的住院病例，使用ICD-10编码J12.1、J20.5、J21.0或B97.4，结果评估集中在2016年至2020年。院内结果包括住院时间、重症监护（ICU）需求和院内全因死亡率。出院后的结果包括 30 天因失代偿再入院、90 天 RSV 相关再入院以及 30 天和 60 天院内死亡率。结果累计确定了 17 483 例 RSV 相关住院，即每百万次住院中有 72.0 例。结果评估包括 12,987 名患者：女性占 55.8%，平均年龄为 74.1 ± 16.4 岁，其中 57% 的患者年龄≥ 75 岁。大多数患者（78.6%）至少患有一种并发症，主要是慢性呼吸系统疾病（56.3%）和心血管疾病（41.3%）或糖尿病（23.5%）。22.4%的患者合并感染，主要是细菌感染（12%）。平均住院时间为 12.3 ± 13.1 天。总体而言，10.9%的患者住进了重症监护室，院内死亡率为7.3%。合并感染病例的院内死亡率更高。在 12 033 名出院时仍存活的患者中，6.5% 的患者在 90 天内因感染 RSV 而再次入院，8.1% 的患者在 30 天内因病情加重而再次入院，5.6% 的患者在 60 天内死亡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Virology 医学-病毒学

CiteScore

22.70

自引率

1.10%

发文量

149

审稿时长

24 days

期刊介绍： The Journal of Clinical Virology, an esteemed international publication, serves as the official journal for both the Pan American Society for Clinical Virology and The European Society for Clinical Virology. Dedicated to advancing the understanding of human virology in clinical settings, the Journal of Clinical Virology focuses on disseminating research papers and reviews pertaining to the clinical aspects of virology. Its scope encompasses articles discussing diagnostic methodologies and virus-induced clinical conditions, with an emphasis on practicality and relevance to clinical practice. The journal publishes on topics that include: • new diagnostic technologies • nucleic acid amplification and serologic testing • targeted and metagenomic next-generation sequencing • emerging pandemic viral threats • respiratory viruses • transplant viruses • chronic viral infections • cancer-associated viruses • gastrointestinal viruses • central nervous system viruses • one health (excludes animal health)